Allspring Global Investments Holdings, LLC Macrogenics Inc Transaction History

Allspring Global Investments Holdings, LLC

$62.1 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	SELL	$9.77 - $21.47 $274,859 - $604,015	-28,133 Reduced 68.9%	12,701 $186,000
Q4 2023 Jan 25, 2024	BUY	$4.48 - $10.11 $71,653 - $161,699	15,994 Added 64.39%	40,834 $392,000
Q3 2023 Oct 27, 2023	BUY	$4.48 - $6.19 $111,283 - $153,759	24,840 New	24,840 $115,000
Q2 2023 Jul 18, 2023	BUY	$4.62 - $7.54 $213,527 - $348,483	46,218 Added 280.28%	62,708 $335,000
Q1 2023 Apr 13, 2023	BUY	$4.82 - $7.24 $34,747 - $52,193	7,209 Added 77.67%	16,490 $118,000
Q4 2022 Jan 23, 2023	BUY	$3.34 - $6.98 $21,546 - $45,027	6,451 Added 227.95%	9,281 $0
Q3 2022 Oct 26, 2022	BUY	$3.01 - $5.22 $8,518 - $14,772	2,830 New	2,830 $9,000
Q2 2022 Jul 25, 2022	SELL	$2.25 - $9.99 $60,988 - $270,788	-27,106 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$8.12 - $16.9 $6,398 - $13,317	788 Added 2.99%	27,106 $238,000
Q4 2021 Jan 28, 2022	BUY	$15.91 - $21.88 $418,719 - $575,837	26,318 New	26,318 $422,000

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

Bellevue Group Ag Kuesnacht, V8

9.93M
Shares

$32.4 Million
0.55% of portfolio
Armistice Capital, LLC New York, NY

6.26M
Shares

$20.4 Million
0.34% of portfolio
Black Rock Inc. New York, NY

5.4M
Shares

$17.6 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.36M
Shares

$14.2 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.54M
Shares

$11.5 Million
0.01% of portfolio

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.

Account